NOTE: This contains archival information which should not be considered current.
New York, NY - June 25, 2018 - Schrӧdinger is pleased to partner with i2Learning to offer a summer STEM week for middle school students. Participating students will use Maestro to visualize small molecules and proteins, and learn how the shape of compounds affects their function - from sugars to enzymes. Students will also learn the chemistry of digestion and how it impacts the design of medicines, as they combine predictive modeling and experimental confirmation to build off scientific concepts based on Next Generation Science Standards. This partnership is part of Schrӧdinger’s STEM outreach program, which seeks to promote the company’s goal to make science accessible, relatable, and creative. By working with i2Learning, Schrӧdinger will enable students and educators to gain real-world experience with state-of-the-art computational tools. Schrӧdinger and i2Learning will work collaboratively to increase excitement about and exposure to science at a young age.
More information can be found at: https://i2camp.org/course-listings/chemical-engineering
About i2Learning
i2 has been developed with the goal of engaging middle school children in the fields of science, technology, engineering and math (STEM). Partnering with some of the world’s leading STEM organizations, i2 broadens a child’s exposure to STEM with a wide variety of new, innovative courses not seen in traditional middle school education. The fun and intimate, hands-on activities of the courses strive to excite and inspire participants about STEM, creating enthusiasm that will hopefully spill over to their schoolwork and school choices in future years.
About Schrödinger
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a cofounder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger’s investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.